PLACENTA-DERIVED ADHERENT (PDA) STEM CELL FOR THE TREATMENT OF ADULTS WITH SARS-COV-2 RELATED ACUTE RESPIRATORY FAILURE AND ARDS (COVID-19)

1 . A method of treating a subject having SARS-CoV-2 related acute respiratory failure (COVID-19), comprising administering to the subject a composition comprising CD10 + , CD34 − , CD105+, CD200+ placental stem cells.

2 . The method of claim 1 , wherein the subject has Acute Respiratory Disease Syndrome (ARDS).

3 . The method of claim 2 , wherein the subject has moderate ARDS.

4 . The method of claim 2 , wherein the subject has severe ARDS.

5 . The method of claim 1 , wherein the composition comprising placental stem cells is administered intravenously.

6 . The method of claim 1 , wherein the composition comprises between 1×10 5 to 1×10 6 , 1×10 6 to 3×10 6 , 3×10 6 to 5×10 6 , 5×10 6 to 1×10 7 , 1×10 7 to 3×10 7 , 3×10 7 to 5×10 7 , 5×10 7 to 1×10 8 , 1×10 8 to 3×10 8 , 3×10 8 to 5×10 8 , 5×10 8 to 1×10 9 , 1×10 9 to 5×10 9 , or 5×10 9 to 1×10 10 placental stem cells.

7 . The method of claim 1 , wherein the composition comprises about 1×10 5 , 3×10 5 , 5×10 5 , 1×10 6 , 3×10 6 , 5×10 6 , 1×10 7 , 3×10 7 , 5×10 7 , 1×10 8 , 3×10 8 , 5×10 8 , 1×10 9 , 5×10 9 , or 1×10 10 placental stem cells.

8 .- 9 . (canceled)

10 . The method of claim 6 , wherein the composition comprises about 100×10 6 placental stem cells.

11 . (canceled)

12 . The method of claim 1 , wherein the treatment results in an increase in oxygenation.

13 . The method of claim 1 , wherein the treatment results in stable oxygenation with a decrease in oxygen utilization.

14 . The method of claim 1 , wherein the treatment results in an improvement in the need for oxygen supplementation.

15 . The method of claim 1 , wherein the treatment results in a decrease in progression to mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

16 . The method of claim 1 , wherein the treatment results in a decrease in duration of mechanical ventilation or ECMO.

17 . The method of claim 1 , wherein the treatment results in a decrease in duration of stay in the intensive care unit.

18 . The method of claim 1 , wherein the treatment results in a decrease in duration of hospital stay.

19 . The method of claim 1 , wherein the treatment results in a decrease in mortality.

20 . The method of claim 1 , wherein the placental stem cells are additionally CD45 − or CD90 + .

21 . The method of claim 1 , wherein the placental stem cells are additionally CD45 − and CD90 + .

22 . The method of claim 1 , wherein the placental stem cells are additionally one or more of CD38 − , CD45 − , CD80 − , CD86 − , CD133 − , HLA-DR,DP,DQ − , SSEA3 − , SSEA4 − , CD29+, CD44+, CD73+, CD90+, CD105+, HLA-A,B,C+, PDL1+, ABC-p+, and/or OCT-4+.

23 . The method of claim 1 , wherein the placental stem cells are additionally one or more of CD117 − , CD133 − , KDR − (VEGFR2 − ), HLA-A,B,C + , HLA-DP,DQ,DR − , or Programmed Death-1 Ligand (PDL1)+.